Allogene Therapeutics (ALLO) Cash from Financing Activities (2018 - 2026)

Allogene Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at $21.1 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 50.98% year-over-year to $21.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.3 million (down 71.1% YoY) and the FY2025 annual result came in at $30.2 million, down 74.15% from the prior year.
• Cash from Financing Activities improved to $21.1 million in Q1 2026 per ALLO's latest filing, from $7.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $108.6 million in Q2 2024 and troughed at $24000.0 in Q2 2022.
• A 5-year average of $15.7 million and a median of $3.2 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 99.25% in 2022, then soared 372916.67% in 2023.
• Over 5 years, Cash from Financing Activities stood at $46000.0 in 2022, then jumped by 236.96% to $155000.0 in 2023, then soared by 3605.16% to $5.7 million in 2024, then surged by 36.84% to $7.9 million in 2025, then jumped by 168.76% to $21.1 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $21.1 million, $7.9 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.